Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial.
Saved in:
| Title: | Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial. |
|---|---|
| Authors: | Roth, Eli M.1 eroth@sterlingresearch.org, Taskinen, Marja-Riitta2, Ginsberg, Henry N.3, Kastelein, John J. P.4, Colhoun, Helen M.5, Robinson, Jennifer G.6, Merlet, Laurence7, Pordy, Robert8, Baccara-Dinet, Marie T.9 |
| Source: | International Journal of Cardiology. Sep2014, Vol. 176 Issue 1, p55-61. 7p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
